Clinical Efficacy

Clinical efficacy of inhaled therapy delivered via the Ellipta inhaler

As well as ease of use, and fewer patients making an error with their inhaler, treatments are needed that show clinical efficacy.^1-6

Quick links

Exacerbations

GO TO SECTION

Lung Function

GO TO SECTION

Symptoms

GO TO SECTION

Switching from MITT to FF/UMEC/VI49

GO TO SECTION

Patient benefits: Summary

GO TO SECTION

Exacerbations

Annual rate of moderate/severe exacerbations and severe exacerbations.^7-9

*p<0.05, **p<0.01 and ***p<0.001; ^†NS. In FULFIL moderate exacerbation was defined as requiring treatment with oral/systemic corticosteroids and/or antibiotics and a severe exacerbation was defined as requiring treatment with inpatient hospitalisation. In IMPACT a moderate exacerbation was defined as one leading to treatment with antibiotics or systemic glucocorticoids, and a severe exacerbation was defined as one resulting in hospitalisation or death.

Click here to learn more about the FULFIL trial

FULFIL was a 24-week randomised, double-blind, double-dummy, multicentre trial in 1810 patients with symptomatic COPD to assess the effects of once-daily triple therapy on lung function and health-related quality of life versus twice-daily dual therapy with an ICS/LABA.⁷ Patients were randomised to once-daily FF/UMEC/VI (100 μg/62.5 μg/25 μg) and twice-daily placebo using the Turbuhaler, or twice-daily BUD/FOR (400 μg/12 μg) using the Turbuhaler and once-daily placebo using the Ellipta inhaler.⁷

Co-primary endpoints were change from baseline in trough FEV₁ and change from baseline in SGRQ total score at Week 24.⁷

Safety profile

FF/UMEC/VI had a safety profile that reflected the known profiles of each component molecule.⁷

In the ITT population, the most common adverse events were nasopharyngitis (FF/UMEC/VI: n=64 [7%]; BUD/FOR: n=43 [5%]) and headache (FF/UMEC/VI: n=44 [5%]; BUD/FOR: n=53 [6%]).⁷

	ITT population, 24 weeks		EXT population, 52 weeks
Events, (%)	FF/UMEC/VI (n=911)	BUD/FOR (n=899)	FF/UMEC/VI (n=210)	BUD/FOR (n=220)
On-treatment adverse events	38.9	37.7	N/R	N/R
On-treatment serious adverse events	5.4	5.7	10.0	12.7
Pneumonia	2.2	0.8	1.9	1.8
On-treatment deaths	<1	<1	N/R	N/R

BUD, budesonide; EXT, extension; FEV₁, forced expiratory volume in 1 second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroids; ITT, intent-to-treat; LABA, long acting β₂-agonist; N/R, not reported; SGRQ, St, George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the IMPACT trial

IMPACT was a 52-week randomised, double-blind, parallel-group, multicentre trial in 10,355 patients with symptomatic COPD and at high risk of exacerbations to assess the benefits of triple therapy versus dual therapy.⁸ Patients were randomised to once-daily FF/UMEC/VI (100 µg/62.5 µg/25 µg), FF/VI (100 µg/25 µg) or UMEC/VI (62.5 µg/25µg) therapy.⁸

The primary endpoint was annual rate of moderate or severe COPD exacerbations during treatment.⁸

Safety profile

FF/UMEC/VI had a similar safety profile to UMEC/VI and FF/VI and there were no new safety findings.⁸

The most common adverse events of special interest were cardiovascular effects (FF/UMEC/VI: n=450 [11%]; FF/VI: n=430 [10%]; UMEC/VI: n=224 [11%]) and pneumonia (FF/UMEC/VI: n=317 [8%]; FF/VI: n=292 [7%]; UMEC/VI: n=97 [5%]).⁸

Events, n(%)	FF/UMEC/VI (n=4151)	FF/VI (n=4134)	UMEC/VI (n=2070)
On-treatment adverse events	2897 (70)	2800 (68)	1429 (69)
On-treatment serious adverse events	895 (22)	850 (21)	470 (23)
On-treatment fatal serious adverse events	68 (2)	76 (2)	49 (2)
Pneumonia	317 (8)	292 (7)	97 (5)

COPD, chronic obstructive pulmonary disorder; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol

Continue or go back to the top

BACK TO TOP

Lung function

Change from baseline in trough FEV₁ and peak FEV₁.^{2-4,7,8,10,11}

image-showing-change-from-baseline-in-trough-FEV1-and-peak-FEV1-in-the-IMPACT,-FULFIL,-EMAX,-UMEC/VI-vs-TIO/OLO,-INTREPID,-and-AERISTO-trials.-In-the-IMPACT-trial-the-least-squares-mean-change-from-baseline-in-trough-FEV1-at-week-52-increased-by-54-millilitres-and-97-millilitres-for-FF/UMEC/VI-versus-UMEC/VI-and-FF/VI-respectively.-In-the-FULFIL-trial-the-least-squares-mean-change-from-baseline-in-trough-FEV1-at-week-52-for-FF/UMEC/VI-versus-BUD/FOR-increased-by-171-millilitres-and-179-millilitres-up-to-24-weeks-and-52-weeks-respectively.-In-the-EMAX-trial-the-least-squares-mean-change-from-baseline-in-trough-FEV1-at-week-24-increased-by-66-millilitres-and-141-millilitres-for-UMEC/VI-versus-UMEC-and-SAL-respectively.-For-UMEC/VI-versus-TIO/OLO-the-least-squares-mean-change-from-baseline-in-trough-FEV1-at-week-8-increased-by-52-millilitres-and-57-millilitres-for-the-ITT-and-MN-population-respectively.-In-the-INTREPID-trial-the-least-squares-mean-change-from-baseline-in-trough-FEV1-at-week-24-increased-by-53-millilitres-for-FF/UMEC/VI-versus-non-Ellipta-MITT-respectively.-In-the-AERISTO-trial-the-least-squares-mean-change-from-baseline-in-trough-FEV1-over-24-weeks-increased-by-87.2-millilitres-for-UMEC/VI-versus-GLY/FOR,-and-the-least-squares-mean-change-from-baseline-in-peak-FEV1-over-24-weeks-increased-by-3.4-millilitres-for-UMEC/VI-versus-GLY/FOR-in-the-per-protocol-population

*p<0.05, **p<0.01 and ***p<0.001; ^†Non-inferiority margin: -50 mL

Click here to learn more about the FULFIL trial

FULFIL was a 24-week randomised, double-blind, double-dummy, multicentre trial in 1810 patients with symptomatic COPD to assess the effects of once-daily triple therapy on lung function and health-related quality of life versus twice-daily dual therapy with an ICS/LABA⁷. Patients were randomised to once-daily FF/UMEC/VI (100 µg/62.5 µg/25 µg) and twice daily placebo using the Turbuhaler, or twice daily BUD/FOR (400 µg/12 µg) using the Turbuhaler and once-daily placebo using the Ellipta inhaler.⁷

Co-primary endpoints were change from baseline in trough FEV₁ and change from baseline in SGRQ total score at Week 24.⁷

Safety profile

FF/UMEC/VI had a safety profile that reflected the known profiles of each component molecule.⁷

In the ITT population, the most common adverse events were nasopharyngitis (FF/UMEC/VI: n=64 [7%]; BUD/FOR: n=43 [5%]) and headache (FF/UMEC/VI: n=44 [5%]; BUD/FOR: n=53 [6%]).⁷

	ITT population, 24 weeks		EXT population, 52 weeks
Events, (%)	FF/UMEC/VI (n=911)	BUD/FOR (n=899)	FF/UMEC/VI (n=210)	BUD/FOR (n=220)
On-treatment adverse events	38.9	37.7	N/R	N/R
On-treatment serious adverse events	5.4	5.7	10.0	12.7
Pneumonia	2.2	0.8	1.9	1.8
On-treatment deaths	<1	<1	N/R	N/R

BUD, budesonide; EXT, extension; FEV₁, forced expiratory volume in 1 second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroids; ITT, intent-to-treat; LABA, long acting β₂-agonist; N/R, not reported; SGRQ, St, George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the IMPACT trial

IMPACT was a 52-week randomised, double-blind, parallel-group, multicentre trial in 10,355 patients with symptomatic COPD and at high risk of exacerbations to assess the benefits of triple therapy versus dual therapy.⁸ Patients were randomised to once-daily FF/UMEC/VI (100 µg/62.5 µg/25 µg), FF/VI (100 µg/25 µg) or UMEC/VI (62.5 µg/25µg) therapy.⁸

The primary endpoint was annual rate of moderate or severe COPD exacerbations during treatment.⁸

Safety profile

FF/UMEC/VI had a similar safety profile to UMEC/VI and FF/VI and there were no new safety findings.⁸

The most common adverse events of special interest were cardiovascular effects (FF/UMEC/VI: n=450 [11%]; FF/VI: n=430 [10%]; UMEC/VI: n=224 [11%]) and pneumonia (FF/UMEC/VI: n=317 [8%]; FF/VI: n=292 [7%]; UMEC/VI: n=97 [5%]).⁸

Events, n(%)	FF/UMEC/VI (n=4151)	FF/VI (n=4134)	UMEC/VI (n=2070)
On-treatment adverse events	2897 (70)	2800 (68)	1429 (69)
On-treatment serious adverse events	895 (22)	850 (21)	470 (23)
On-treatment fatal serious adverse events	68 (2)	76 (2)	49 (2)
Pneumonia	317 (8)	292 (7)	97 (5)

COPD, chronic obstructive pulmonary disorder; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the EMAX trial

The EMAX trial was a large 24-week randomised, double-blind, double-dummy, parallel-group trial of UMEC/VI 62.5/25 μg (once-daily), versus UMEC 62.5 μg (once-daily) and SAL 50 μg (twice-daily).¹¹ It was the first randomised controlled trial to assess the efficacy and safety of a LAMA/LABA in symptomatic patients with a low risk of exacerbation who were not using ICS.¹¹

The primary endpoint was trough FEV₁ at Week 24.¹¹

Safety profile

Safety profiles were similar between treatment groups.¹¹

The most frequent adverse event was nasopharyngitis (UMEC/VI: n=68 [8%]; UMEC: n=87 [11%]; SAL: n=84 [10%]).¹¹

Events, n(%)	UMEC/VI (n=812)	UMEC (n=804)	SAL (n=809)
Adverse events	315 (39)	316 (39)	314 (39)
Non-fatal serious adverse events	46 (6)	31 (4)	38 (5)
Fatal serious adverse events	4 (<1)	4 (<1)	0

Adapted with permission from Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20:238 under a Creative Commons License (https://creativecommons.org/licenses/by/4.0).

FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LABA, long acting β₂-agonist; LAMA, long-acting muscarinic antagonist; QD, once a day; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the study investigating UMEC/VI versus TIO/OLO

A randomised, open-label study in patients with symptomatic COPD (NCT02799784) investigated the efficacy of once-daily UMEC/VI* versus TIO/OLO.³

Safety profile

UMEC/VI and TIO/OLO had similar safety profiles.^2,3

In the ITT and MN populations the most frequently reported adverse events were upper respiratory tract infections (ITT, UMEC/VI: n=11 [5%]; TIO/OLO: n=14 [6%]; MN, UMEC/VI: n=6 [4%]; TIO/OLO: n=6 [4%]).^2,3

	ITT population		MN population
Events, n(%)	UMEC/VI (n=235)	TIO/OLO (n=230)	UMEC/VI (n=147)	TIO/OLO (n=145)
Adverse events	59 (25)	71 (31)	35 (24)	42 (29)
Non-fatal serious adverse events	3 (1)	2 (<1)	1 (<1)	1 (<1)
Fatal serious adverse events	0	0	0	0

The MN population included all patients who had not received a maintenance treatment (LAMA, LABA alone or in combination ± ICS) for COPD in the 30 days that records were kept prior to screening.*Delivered dose 55/22 μg.¹²

COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; MN, maintenance; OLO, olodaterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the INTREPID study

INTREPID was a 24-week, multicentre, randomised, open-label, Phase IV effectiveness study comparing once-daily FF/UMEC/VI single-inhaler triple therapy delivered by the Ellipta inhaler with any licenced non-Ellipta MITT in 3092 patients with COPD in a usual clinical practice setting in 5 European countries.¹⁰

The primary effectiveness outcome was the proportion of responders based on the CAT score at Week 24.¹⁰

Safety profile

FF/UMEC/VI had a similar safety profile to non-ELLIPTA MITT in a usual clinical care setting, including incidence of pneumonia.¹⁰

Treatment-emergent adverse events, n (%)	FF/UMEC/VI (n=1545)	Non-ELLIPTA MITT (n=1547)
Adverse events	250 (16)	151 (10)
Serious adverse events	114 (7)	114 (7)
Pneumonia serious adverse event of special interest	27 (2)	32 (2)
Fatal serious adverse events	8 (<1)	8 (<1)

CAT, COPD Assessment Test; FF, fluticasone furoate; MITT, multiple inhaler triple therapy; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the AERISTO trial

AERISTO was a 24-week randomised, double-blind, double-dummy, parallel-group non-inferiority study in 1119 patients with symptomatic moderate-to-very severe COPD.⁴

Co-primary endpoints were change from baseline in trough FEV₁ and peak change from baseline in 2-h post dose FEV₁ over 24 weeks.⁴

Safety profile

UMEC/VI and GLY/FOR had similar safety profiles.⁴

The most common adverse event in both treatment groups was headache (UMEC/VI: n=41 [7%]; GLY/FOR: n=34 [6%]).⁴

Treatment-emergent adverse events, n (%)	UMEC/VI (n=552)	GLY/FOR (n=552)
Adverse events	248 (45)	226 (41)
Serious adverse events	40 (7)	32 (6)
Fatal serious adverse events	3 (<1)	3 (<1)

COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; GLY, glycopyrrolate; FOR, formoterol; UMEC, umeclidinium; VI, vilanterol

Continue or go back to the top

BACK TO TOP

Symptoms

Breathlessness, daily symptoms and health status.^2,3,10,11

*p <0.05; **p <0.01; ***p <0.001. A clinically meaningful response for CAT responders in INTREPID was defined as a decrease in CAT score of ≥2 units from baseline.

Click here to learn more about the EMAX trial

The EMAX trial was a large 24-week randomised, double-blind, double-dummy, parallel-group trial of UMEC/VI 62.5/25 μg (once-daily), versus UMEC 62.5 μg (once-daily) and SAL 50 μg (twice-daily).¹¹ It was the first randomised controlled trial to assess the efficacy and safety of a LAMA/LABA in symptomatic patients with a low risk of exacerbation who were not using ICS.¹¹

The primary endpoint was trough FEV₁ at Week 24.¹¹

Safety profile

Safety profiles were similar between treatment groups.¹¹

The most frequent adverse event was nasopharyngitis (UMEC/VI: n=68 [8%]; UMEC: n=87 [11%]; SAL: n=84 [10%]).¹¹

Events, n(%)	UMEC/VI (n=812)	UMEC (n=804)	SAL (n=809)
Adverse events	315 (39)	316 (39)	314 (39)
Non-fatal serious adverse events	46 (6)	31 (4)	38 (5)
Fatal serious adverse events	4 (<1)	4 (<1)	0

Adapted with permission from Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20:238 under a Creative Commons License (https://creativecommons.org/licenses/by/4.0).

FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LABA, long acting β₂-agonist; LAMA, long-acting muscarinic antagonist; QD, once a day; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the study investigating UMEC/VI versus TIO/OLO

A randomised, open-label study in patients with symptomatic COPD (NCT02799784) investigated the efficacy of once-daily UMEC/VI* versus TIO/OLO.³

Safety profile

UMEC/VI and TIO/OLO had similar safety profiles.^2,3

In the ITT and MN populations the most frequently reported adverse events were upper respiratory tract infections (ITT, UMEC/VI: n=11 [5%]; TIO/OLO: n=14 [6%]; MN, UMEC/VI: n=6 [4%]; TIO/OLO: n=6 [4%]).^2,3

	ITT population		MN population
Events, n(%)	UMEC/VI (n=235)	TIO/OLO (n=230)	UMEC/VI (n=147)	TIO/OLO (n=145)
Adverse events	59 (25)	71 (31)	35 (24)	42 (29)
Non-fatal serious adverse events	3 (1)	2 (<1)	1 (<1)	1 (<1)
Fatal serious adverse events	0	0	0	0

The MN population included all patients who had not received a maintenance treatment (LAMA, LABA alone or in combination ± ICS) for COPD in the 30 days that records were kept prior to screening.*Delivered dose 55/22 μg.¹²

COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; MN, maintenance; OLO, olodaterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol

Click here to learn more about the INTREPID study

INTREPID was a 24-week, multicentre, randomised, open-label, Phase IV effectiveness study comparing once-daily FF/UMEC/VI single-inhaler triple therapy delivered by the Ellipta inhaler with any licenced non-Ellipta MITT in 3092 patients with COPD in a usual clinical practice setting in 5 European countries.¹⁰

The primary effectiveness outcome was the proportion of responders based on the CAT score at Week 24.¹⁰

Safety profile

FF/UMEC/VI had a similar safety profile to non-ELLIPTA MITT in a usual clinical care setting, including incidence of pneumonia.¹⁰

Treatment-emergent adverse events, n (%)	FF/UMEC/VI (n=1545)	Non-ELLIPTA MITT (n=1547)
Adverse events	250 (16)	151 (10)
Serious adverse events	114 (7)	114 (7)
Pneumonia serious adverse event of special interest	27 (2)	32 (2)
Fatal serious adverse events	8 (<1)	8 (<1)

CAT, COPD Assessment Test; FF, fluticasone furoate; MITT, multiple inhaler triple therapy; UMEC, umeclidinium; VI, vilanterol

Continue or go back to the top

BACK TO TOP

Switching from MITT to FF/UMEC/V¹³

This study examined the impact of switching from MITT to FF/UMEC/VI on moderate and severe exacerbations in a real-world setting.¹³ An analysis was carried out using the Optum Research Database in patients with COPD.¹³ Patients aged ≥40 years, initiated on FF/UMEC/VI between September 1, 2017 and December 31, 2018 (with an index date of the earliest pharmacy fill for FF/UMEC/VI), and that were on MITT for ≥30 consecutive days during the 12 months prior to the index date were included.¹³

Impact of initiating FF/UMEC/VI on exacerbation frequency (overall population)
Impact of initiating FF/UMEC/VI on exacerbation frequency (patients with any pre-index exacerbation)

Mean number of exacerbations in the overall patient population (N=912) for FF/UMEC/VI versus MITT.¹³

bar-graph-showing-the-mean-number-of-exacerbations-in-the-overall-patient-population-for-FF/UMEC/VI-versus-MITT-in-a-study-examining-the-impact-of-switching-from-MITT-to-FF/UMEC/VI-on-moderate-and-severe-exacerbations-in-a-real-world-setting.-For-MITT-the-mean-number-of-exacerbations-was-1.37-1.07-and-0.30-for-any-exacerbation-moderate-exacerbations-and-severe-exacerbations-repectively.-For-FF/UMEC/VI-the-mean-number-of-exacerbations-was-1.20-0.91-and-0.29-for-any-exacerbation-moderate-exacerbations-and-severe-exacerbations-repectively.-There-was-a-12-percent-relative-reduction-in-exacerbations-between-treatments-for-any-exacerbation,-a-15-percent-relative-reduction-between-treatments-for-moderate-exacerbations,-and-no-difference for-severe-exacerbations

Adapted with permission from Bogart M, Ismaila AS, Bangalore M, et al. COPD Exacerbations in Patients Switched from Multiple-Inhaler Triple Therapy to FF/UMEC/VI. American College of Chest Physicians - CHEST 2021. Poster presentation.

Any exacerbation includes moderate and severe exacerbations

Mean number of exacerbations in the subpopulation of patients with any pre-index exacerbation (N=569) for FF/UMEC/VI versus MITT.¹³

bar-graph-showing-the-mean-number-of-exacerbations-in-the-subpopulation-of-patients-with-any-pre-index-exacerbation-for-FF/UMEC/VI-versus-MITT,-in-a-study-examining-the-impact-of-switching-from-MITT-to-FF/UMEC/VI-on-moderate-and-severe-exacerbations-in-a-real-world-setting.-For-MITT-the-mean-number-of-exacerbations-was-2.19-1.71-and-0.48-for-any-exacerbation-moderate-exacerbations-and-severe-exacerbations-repectively.-For-FF/UMEC/VI-the-mean-number-of-exacerbations-was-1.56-1.21-and-0.36-for-any-exacerbation-moderate-exacerbations-and-severe-exacerbations-repectively. There-was-a-29-percent-relative-reduction-in-exacerbations-between-treatments-for-any-exacerbation,-a-30-percent-relative-reduction-between-treatments-for-moderate-exacerbations,-and-a-25-percent-relative-reduction-for-severe-exacerbations

Adapted with permission from Bogart M, Ismaila AS, Bangalore M, et al. COPD Exacerbations in Patients Switched from Multiple-Inhaler Triple Therapy to FF/UMEC/VI. American College of Chest Physicians - CHEST 2021. Poster presentation.

Any exacerbation includes moderate and severe exacerbations

Continue or go back to the top

BACK TO TOP

Patient benefits: Summary

Data from clinical trials demonstrates the clinical efficacy of inhaled therapy delivered via the Ellipta inhaler.^2-4,7,8

Continue your journey

Unmet need

Explore the unmet need of inhaler therapy

GO TO UNMET NEED

Technical performance

Explore the technical performance of inhalers

GO TO TECHNICAL PERFORMANCE

Patient benefits

Explore the benefits of inhaled therapy for patients with COPD, including clinical efficacy

GO TO PATIENT BENEFITS

Abbreviations

BUD, budesonide; CAT, COPD Assessment Test; CFB, change from baseline; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms-COPD; EXT, extension; FEV₁, forced expiratory volume in 1 second; FF, fluticasone furoate; FOR, formoterol; GLY, glycopyrrolate; ICS, inhaled corticosteroids; ITT, intent-to-treat; LABA, long acting β₂-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; MITT, multiple-inhaler triple therapy; MN, maintenance-na ve; N/R, not reported; NS, not significant; OLO, olodaterol; PP, per-protocol; SABA, short-acting beta agonist; SAC-TDI, self-administered computerised-Transition Dyspnoea Index; SAL, salmeterol; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.

Ellipta is owned by or licensed to the GSK Group of Companies. Turbuhaler is a registered trademark of AstraZeneca.

References

Molimard M, Raherison C, Lignot S, et al. Eur Respir J. 2017;49:1601794.
Alcázar Navarrete B, Boucot I, Naya I, et al. Pulm Ther. 2018;4:171-183.
Feldman GJ, Sousa AR, Lipson DA, et al. Adv Ther. 2017;34:2518-2533.
Maltais F, Ferguson GT, Feldman GJ, et al. Adv Ther. 2019;36:2434-2449.
Melani AS, Bonavia M, Cilenti V, et al. Respir Med. 2011;105:930-938.
Usmani OS, Lavorini F, Marshall J, et al. Respir Res. 2018;19:10.
Lipson DA, Barnacle H, Birk R, et al. Am J Respir Crit Care Med. 2017;196:438-446.
Lipson DA, Barnhart F, Brealey N, et al. N Engl J Med. 2018;378:1671-1680.
Panettieri R, Bangalore M, Camargo Jr CA, et al. American College of Chest Physicians - CHEST 2021. 2021;160:A1818-A1821.
Halpin DMG, Worsley S, Ismaila AS, et al. ERJ Open Res. 2021;7:00950-2020.
Maltais F, Bjermer L, Kerwin EM, et al. Respir Res. 2019;20:238.
Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/5423/smpc#gref Accessed August 2021
Bogart M, Ismaila A, Bangalore M, Bunner S, Bengtson L. COPD Exacerbations in Patients Switched from Multiple-Inhaler Triple Therapy to FF/UMEC/VI. American College of Chest Physicians - CHEST 2021. Poster presentation.

NX-GBL-UCV-WCNT-220001 | Date of preparation: August 2022

You are now leaving GSK’s website